Wall Street brokerages forecast that Minerva Surgical, Inc. (NASDAQ:UTRS – Get Rating) will announce ($0.31) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Minerva Surgical’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.32). The firm is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Minerva Surgical will report full-year earnings of ($1.03) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.96). For the next financial year, analysts forecast that the business will post earnings of ($0.88) per share, with EPS estimates ranging from ($0.90) to ($0.86). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Minerva Surgical.
UTRS has been the topic of several research analyst reports. Piper Sandler lowered their price objective on Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Wednesday, March 9th. Zacks Investment Research cut Minerva Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Minerva Surgical currently has a consensus rating of “Buy” and an average target price of $11.70.
Several institutional investors have recently modified their holdings of UTRS. Virtu Financial LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $54,000. Renaissance Technologies LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $78,000. BlackRock Inc. acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $88,000. Millennium Management LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $134,000. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Minerva Surgical during the 4th quarter worth approximately $386,000. Institutional investors and hedge funds own 42.40% of the company’s stock.
About Minerva Surgical (Get Rating)
Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.